MYGN
NASDAQ · Biotechnology
Myriad Genetics Inc
$4.56
+0.06 (+1.33%)
Open$4.42
Previous Close$4.50
Day High$4.63
Day Low$4.39
52W High$8.59
52W Low$3.53
Volume—
Avg Volume1.33M
Market Cap428.79M
P/E Ratio—
EPS$-4.32
SectorBiotechnology
Analyst Ratings
Sell
16 analysts
Price Target
+808.8% upside
Current
$4.56
$4.56
Target
$41.44
$41.44
$29.39
$41.44 avg
$63.29
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 856.04M | 802.14M | 74.53M |
| Net Income | -379,896,898 | -320,377,818 | -15,758,896 |
| Profit Margin | -44.4% | -42.2% | -21.1% |
| EBITDA | -346,256,688 | -308,230,747 | -16,042,014 |
| Free Cash Flow | — | — | -13,316,178 |
| Rev Growth | +6.7% | +6.7% | +5.3% |
| Debt/Equity | 0.33 | 0.33 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |